Delayed elimination of SN-38 in cancer patients with severe renal failure

Drug Metabolism and Disposition

Volumn 39, Issue 2, 2011, Pages 161-164

  Fujita, Ken Ichi ^a   Sunakawa, Yu ^a   Miwa, Keisuke ^a   Akiyama, Yuko ^a   Sugiyama, Minako ^a   Kawara, Kaori ^a   Ishida, Hiroo ^a   Yamashita, Keishi ^a   Mizuno, Keiko ^a   Saji, Shigehira ^a   Ichikawa, Wataru ^a   Yamamoto, Wataru ^a   Nagashima, Fumio ^a   Miya, Toshimichi ^a   Narabayashi, Masaru ^a   Ando, Yuichi ^a   Hirose, Takashi ^a   Sasaki, Yasutsuna ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSIS; DISEASE SEVERITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH CANCER;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 79251496687     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035451     Document Type: Article

References (9)

1. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M, and Sasaki Y (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255-1259.
2. Czock D, Rasche FM, Boesler B, Shipkova M, and Keller F (2009) Irinotecan in cancer patients with end-stage renal failure. Ann Pharmacother 43:363-369.
3. de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A, and Verweij J (2008) Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 84:254-262.
4. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, et al. (2007) Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497-504.
5. Nishio T, Takamura N, Nishii R, Tokunaga J, Yoshimoto M, and Kawai K (2008) Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition. Nephrol Dial Transplant 23:2304-2310.
6. Nolin TD, Naud J, Leblond FA, and Pichette V (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898-903.
7. Nozawa T, Minami H, Sugiura S, Tsuji A, and Tamai I (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434-439.
8. Sun H, Frassetto L, and Benet LZ (2006) Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109:1-11. (Pubitemid 41740811)
9. Vénat-Bouvet L, Saint-Marcoux F, Lagarde C, Peyronnet P, Lebrun-Ly V, and Tubiana-Mathieu N (2007) Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered. Anticancer Drugs 18:977-980. (Pubitemid 47220719)